Ayano Watanabe

<scp>BCL</scp>2 and <scp>BCL</scp>xL are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells

Ayano Watanabe, Shinji Yasuhira, Tsuyoshi Inoue et al. · Experimental Dermatology · 2013 · 28 citations · Full text

Medicine, Cancer Biology, Oncology +16

Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death

Shuya Kasai, Takuya Sasaki, Ayano Watanabe et al. · Oncology Letters · 2017 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4

Takehiro Yamaguchi, Ayano Watanabe, Masako Tanaka et al. · Journal of Pharmacological Sciences · 2018 · 20 citations · Full text

Medicine, Cardiology, Pharmacology +14

Polymorphisms and expression of toll-like receptors in autoimmune thyroid diseases

Naoya Inoue, Yuka Katsumata, Mikio Watanabe et al. · Autoimmunity · 2016 · 14 citations

Life Sciences, Endocrinology, Genetics +17

Increases of CD80 and CD86 Expression on Peripheral Blood Cells and their Gene Polymorphisms in Autoimmune Thyroid Disease

Ayano Watanabe, Naoya Inoue, Mikio Watanabe et al. · Immunological Investigations · 2019 · 13 citations

Life Sciences, Genetics, Immunology +14